Open access
Open access
Powered by Google Translator Translator

General Hematology

Case report and brief review | Severe thrombotic complications secondary to antiphospholipid syndrome and undiagnosed systemic lupus erythematosus.

20 Sep, 2022 | 13:17h | UTC

Severe thrombotic complications secondary to antiphospholipid syndrome and undiagnosed systemic lupus erythematosus – Canadian Medical Association Journal

 


AHA Scientific Statement | Management of patients at risk for and with left ventricular thrombus.

16 Sep, 2022 | 13:00h | UTC

Management of Patients at Risk for and With Left Ventricular Thrombus: A Scientific Statement From the American Heart Association – Circulation

 


Review | Obesity and contraceptive use: impact on cardiovascular risk.

16 Sep, 2022 | 12:53h | UTC

Obesity and contraceptive use: impact on cardiovascular risk – ESC Heart Failure

News Release: Combined birth control pill linked with increased risk of blood clots in obese women – European Society of Cardiology

 


M-A | Blood type linked to the risk of stroke before age 60.

13 Sep, 2022 | 13:17h | UTC

Contribution of Common Genetic Variants to Risk of Early Onset Ischemic Stroke – Neurology (link to abstract – $ for full-text)

News Releases:

Is your blood type linked to your risk of stroke before age 60? – American Academy of Neurology

Blood Type Linked To Stroke Risk Before 60 – University of Maryland

 


Systematic Review | Hypoxia‐inducible factor stabilizers for the anemia of chronic kidney disease.

8 Sep, 2022 | 14:35h | UTC

Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease – Cochrane Library

Summary: Are hypoxia-inducible factor stabilisers effective for management of anaemia among people with chronic kidney disease? – Cochrane Library

 


48-week follow-up of a RCT | Pegcetacoplan vs. Eculizumab in patients with paroxysmal nocturnal hemoglobinuria.

8 Sep, 2022 | 14:29h | UTC

Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial – The Lancet Haematology (link to abstract – $ for full-text)

Original Study: Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria – New England Journal of Medicine

 

Commentary on Twitter (thread – click for more)

 


Opinion | Tranexamic acid for safer surgery: the time is now.

7 Sep, 2022 | 12:37h | UTC

Tranexamic acid for safer surgery: the time is now – British Journal of Surgery

Related:

#ACC22 – RCT: Tranexamic acid reduces the risk of bleeding in patients undergoing noncardiac surgery.

Update on applications and limitations of perioperative tranexamic acid.

RCT | Effect of high- vs. low-dose tranexamic acid infusion on need for red blood cell transfusion and adverse events in patients undergoing cardiac surgery.

Safety of tranexamic acid in hip and knee arthroplasty in high-risk patients – this large observational study did not show an increased risk for venous thromboembolism, myocardial infarction, seizures, ischemic strokes, or transient ischemic attacks, irrespective of patient high-risk status at baseline

M-A: Intravenous tranexamic acid in surgical patients is not associated with increased risk of thromboembolic events and mortality

 


Brief Review | Thromboprophylaxis in critical care.

6 Sep, 2022 | 14:41h | UTC

Thromboprophylaxis in critical care – Intensive Care Medicine

 


Review | The use of whole blood transfusion in trauma.

6 Sep, 2022 | 14:15h | UTC

The Use of Whole Blood Transfusion in Trauma – Current Anesthesiology Reports

 


Systematic Review | Hydroxyurea for sickle cell disease.

5 Sep, 2022 | 14:14h | UTC

Hydroxyurea (hydroxycarbamide) for sickle cell disease – Cochrane Library

Summary: Hydroxyurea (also known as hydroxycarbamide) for people with sickle cell disease – Cochrane Library

 


Systematic Review | The effect of heparin and its preparations on disseminated intravascular coagulation mortality and hospitalization.

1 Sep, 2022 | 11:34h | UTC

The Effect of Heparin and Its Preparations on Disseminated Intravascular Coagulation Mortality and Hospitalization: A Systematic Review – International Journal of Clinical Practice

 


#ESCCongress | In critically ill patients with COVID-19, full-dose anticoagulation reduced thrombotic events but increased the risk of bleeding.

30 Aug, 2022 | 12:12h | UTC

Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients with COVID-19: COVID-PACT – Circulation

News Release: Trial supports full-dose anticoagulation to prevent blood clots in COVID-19 patients – European Society of Cardiology

Related:

Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library

Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week – Journal of the American College of Cardiology

Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials – Journal of Thrombosis and Thrombolysis

Efficacy and safety of intensified versus standard prophylactic anticoagulation therapy in patients with Covid-19: a systematic review and meta-analysis – Open Forum Infectious Diseases

Point/Counterpoint: Should therapeutic heparin be administered to acutely ill hospitalized patients with COVID-19?

 

Commentary on Twitter

 


#ESCCongress – RCT | In patients with rheumatic heart disease–associated atrial fibrillation, treatment with a Vitamin K antagonist led to a lower rate of cardiovascular events or death compared to Rivaroxaban.

29 Aug, 2022 | 12:33h | UTC

Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Trial backs standard of care for rheumatic heart disease and atrial fibrillation – European Society of Cardiology

Commentary: INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF – TCTMD

 

Commentary on Twitter

 


Review | Blood transfusion reactions.

23 Aug, 2022 | 12:50h | UTC

Blood Transfusion Reactions—A Comprehensive Review of the Literature including a Swiss Perspective – Journal of Clinical Medicine

 


Single-arm phase 2 study | Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent alpha-thalassaemia or beta-thalassaemia.

18 Aug, 2022 | 12:40h | UTC

Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study – The Lancet (link to abstract – $ for full-text)

Commentary: PK Modulator Shows Promise in Thalassemia — In small study, mitapivat increased hemoglobin in 80% of non-transfusion-dependent patients – MedPage Today (free registration required)

 


Guideline | Use of COVID-19 convalescent plasma.

17 Aug, 2022 | 14:28h | UTC

Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma – Annals of Internal Medicine

Editorial: The Fast and the Furious: Chasing a Clinical Niche for COVID-19 Convalescent Plasma – Annals of Internal Medicine

News Release: The AABB releases clinical practice guidelines for the appropriate use of COVID-19 convalescent plasma – American College of Physicians

 


M-A | Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients.

15 Aug, 2022 | 12:27h | UTC

Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials – Journal of Thrombosis and Thrombolysis

Related:

Efficacy and safety of intensified versus standard prophylactic anticoagulation therapy in patients with Covid-19: a systematic review and meta-analysis – Open Forum Infectious Diseases

Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library

Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week – Journal of the American College of Cardiology

Point/Counterpoint: Should therapeutic heparin be administered to acutely ill hospitalized patients with COVID-19?

 


Review | Plasma exchange in the intensive care unit.

15 Aug, 2022 | 12:19h | UTC

Plasma exchange in the intensive care unit: a narrative review – Intensive Care Medicine

 

Commentary on Twitter

 


Consensus Guidance | Thromboprophylaxis for venous thromboembolism prevention in hospitalized patients with cirrhosis.

12 Aug, 2022 | 14:54h | UTC

Thromboprophylaxis for venous thromboembolism prevention in hospitalized patients with cirrhosis: Guidance from the SSC of the ISTH – Journal of Thrombosis and Haemostasis

 


Review | Thrombotic microangiopathy in children.

5 Aug, 2022 | 13:56h | UTC

Thrombotic microangiopathy in children – Pediatric Nephrology (if the link is paywalled, try this one)

 


Cohort Study | Incidence of acute chest syndrome in children with sickle cell disease following implementation of the 13-valent pneumococcal conjugate vaccine.

3 Aug, 2022 | 13:53h | UTC

Incidence of Acute Chest Syndrome in Children With Sickle Cell Disease Following Implementation of the 13-Valent Pneumococcal Conjugate Vaccine in France – JAMA Network Open

 

Commentary on Twitter

 


Systematic Review | Stem cell transplantation for systemic sclerosis.

1 Aug, 2022 | 12:10h | UTC

Stem cell transplantation for systemic sclerosis – Cochrane Library

Summary: Stem cell transplantation for the treatment of systemic sclerosis – Cochrane Library

 


Systematic Review | Antiplatelet agents for the treatment of deep venous thrombosis.

26 Jul, 2022 | 12:44h | UTC

Antiplatelet agents for the treatment of deep venous thrombosis – Cochrane Library

Summary: Aspirin and similar drugs for the treatment of deep vein thrombosis (DVT) – Cochrane Library

 


RCT | Ticagrelor is ineffective for reducing vaso-occlusive crises in pediatric sickle cell disease.

25 Jul, 2022 | 12:50h | UTC

Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study – Blood

 


EASL Clinical Practice Guidelines on hemochromatosis.

18 Jul, 2022 | 11:47h | UTC

EASL Clinical Practice Guidelines on haemochromatosis – Journal of Hepatology

 


Stay Updated in Your Specialty

No spam, just news.